A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of 2 doses of MIN-117 in Adult Subjects with Major Depressive Disorder
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2017
At a glance
- Drugs MIN 117 (Primary) ; Paroxetine
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Minerva Neurosciences
- 18 Aug 2016 Status changed from active, no longer recruiting to completed.
- 01 Jun 2016 Data from this trial will be presented at the Jefferies 2016 Healthcare Conference, according to a Minerva Neurosciences media release.
- 31 May 2016 The trial was completed in Latvia (end date:12 Apr 2016).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History